Paratek Pharmaceuticals, Inc. (PRTK) News
Filter PRTK News Items
PRTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTK News Highlights
- For PRTK, its 30 day story count is now at 6.
- Over the past 6 days, the trend for PRTK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about PRTK are SG.
Latest PRTK News From Around the Web
Below are the latest news stories about PARATEK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PRTK as an investment opportunity.
Paratek Pharmaceuticals (NASDAQ:PRTK) investors are sitting on a loss of 83% if they invested five years agoLong term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut... |
7 Growth Stocks That Are Too Cheap to Ignore Right NowAlthough riskier than usual, these cheap growth stocks to buy now may help liven up your portfolio during these strange times. |
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q1 2023 Earnings Call TranscriptParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q1 2023 Earnings Call Transcript May 9, 2023 Operator: Greetings. And welcome to the Paratek Pharmaceuticals’ First Quarter 2023 Earnings Conference Call. As a reminder, this conference is being recorded, Tuesday, May 9, 2023. It is now my pleasure to turn the conference over to Sarah Higgins, Vice President of Finance […] |
Q1 2023 Paratek Pharmaceuticals Inc Earnings CallQ1 2023 Paratek Pharmaceuticals Inc Earnings Call |
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue EstimatesParatek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) |
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and internation |
There's No Escaping Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Muted Revenues Despite A 77% Share Price RiseParatek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shareholders would be excited to see that the share price has had a great... |
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid |
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2022 Earnings Call TranscriptParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Greetings, and welcome to the Paratek Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Higgins, Vice President of Finance and Principal Accounting Officer. […] |